Slide 1: 2020 Second Quarter Results
2020 Second Quarter Results Gentherm, Inc. August 4, 2020 Exhibit 99.2
Slide 2: Forward-Looking Statement
Forward-Looking Statement Except for historical information contained herein, statements in this presentation are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Genthe
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures* In addition to the results reported in accordance with GAAP throughout this presentation, the Company has provided information regarding Adjusted EBITDA and Adjusted EPS, each a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings (loss) bef
Slide 4: 2Q 2020 Highlights
2Q 2020 Highlights Strong execution despite challenging conditions Continued to outperform in each of the key automotive markets $300M in Automotive new business awards Drove double digit revenue growth in Medical - both year over year and sequentially Reduced operating expense by 30% year over year
Slide 5: Automotive 2Q 2020 Highlights
Automotive 2Q 2020 Highlights Continued momentum in Automotive Recognized by General Motors as a 2019 Supplier of the Year Winner 30 Vehicle launches with 29 OEMs Multiple CCS® product launches Acura MDX Chevrolet Bolt / Blazer Chevrolet Silverado GMC Sierra Hongqi HS7 KIA K5 / Optima Launched phase
Slide 6: Automotive Awards
Automotive Awards Record win rate for new business awards $300M in awards in 2Q across 11 OEMs Over 90% win rate in the quarter Multiple CCS® awards BMWCadillac FordGM BEV Platform Hyundai Steering heater awards across 5 OEMs Expanded business with Toyota with seat heater awards for Lexus RX / NX an
Slide 7: Medical 2Q 2020 Highlights
Medical 2Q 2020 Highlights Continued strong growth in the Medical business Record quarterly revenue; up 18% year over year Continued revenue growth in Blanketrol® equipment globally to support temperature management of COVID-19 patients Hemotherm® now able to be utilized for extracorporeal membrane
Slide 8: Summary
Summary Positioned well to continue to deliver over the long term Executed against strategic plan Focused growth Divested non-core businesses Realigned cost structure Bringing innovative solutions to market Remain highly focused on strong execution Capabilities to pivot resources to meet immediate c
Slide 9: Selected Income Statement Data
Selected Income Statement Data 2020 2019 2020 2019 Product Revenues $ 136,061 $ 243,326 $ 364,674 $ 501,247 Gross Margin 26,735 72,714 92,802 148,021 Gross Margin % 19.6% 29.9% 25.4% 29.5% Operating Expenses 36,632 52,657 83,998 106,119 Operating (Loss) Income (9,897) 20,057 8,804 41,902 Adjusted EB
Slide 10: Selected Balance Sheet Data
Selected Balance Sheet Data June 30, 2020 December 31, 2019 Cash and Cash Equivalents $ 209,170 $ 50,443 Restricted Cash 2,505 2,505 Total Assets 823,370 727,386 Debt 200,599 80,624 Current 2,500 2,500 Non-Current 198,099 78,124 Revolving LOC Availability 159,342 392,325 Total Liquidity 368,512 442,
Slide 11: Gentherm
((l)) GENTHERM
Slide 12: Reconciliation of Net (Loss) Income to Adjusted EBITDA
Reconciliation of Net (Loss) Income to Adjusted EBITDA 2020 2019 2020 2019 Net (Loss) Income $ (10,322) $ 2,751 $ 1,551 $ 11,165 Add Back: Income Tax Expense 205 5,548 5,611 12,443 Interest Expense 1,361 1,240 2,109 2,608 Depreciation and Amortization 9,847 11,094 20,000 22,074 Adjustments: Restruct
Slide 13: Reconciliation of Adjusted EPS
Reconciliation of Adjusted EPS 2020 2019 2020 2019 Diluted EPS - As Reported $ (0.32) $ 0.08 $ 0.05 $ 0.33 Acquisition Transaction Expenses — 0.01 — 0.01 Non-Cash Purchase Accounting Impacts 0.07 0.08 0.13 0.15 Unrealized Currency Loss (Gain) 0.05 — 0.07 (0.02) Restructuring Expenses (0.02) 0.04 0.1
Slide 14: Gentherm - Technology to the next degree
(()))) GENTHERM Technology to the next degree™